Independent fund research. Built on SEC filings.

How we research funds

ETF · Technology Sector · Virtus

Virtus Biotech Clinical Trials ETF (BBC)

Ticker BBC · · Holdings as of Jul 31, 2026

Expense ratio
0.65%$65/yr per $10k
5-yr return
−4.3%annualized
1-yr return
+63.8%as of Dec 2025
Net assets
$46.4Mall share classes
Holdings
132

Bottom line

Is BBC a good fund? The bottom line

BBC is an actively managed technology sector ETF from Virtus.

Its expense ratio is 0.65% — about $65 a year on every $10,000 invested, cheaper than 63% of technology sector funds we track.

It returned +63.8% over one year, −4.3% a year over five years, +3.3% a year over ten (as of Dec 31, 2025, per its prospectus).

With $46.4 million in net assets and 132 holdings, its largest position is Dreyfus Government Cash Manage (3.5%) and the top 10 make up 14.3% of the portfolio.

What to watch

  • 5-year return in the bottom quarter of its category
  • Small fund ($46.4 million) — small funds are likelier to close

Updated Nov 19, 2026

What BBC invests in

The Virtus Biotech Clinical Trials ETF (formerly, Virtus LifeSci Biotech Clinical Trials ETF) (the Fund ) seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index (the Underlying Index ).

Under normal market conditions, the Fund will invest not less than 80% of its assets in component securities of the Underlying Index. The Underlying Index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ( lead drug ) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval. The Underlying Index is sponsored by LifeSci Index Partners, LLC (the Index Provider ). The Index Provider utilizes a selection committee comprised of its employees (the Index Committee ) that is responsible, pursuant to the rules included in the methodology for the Underlying Index, for making certain determinations for the Underlying Index, as more fully described below. The Index Committee utilizes various public data sources to make determinations, including…

From the fund's prospectus (filed Feb 27, 2026).

BBC performance

Fund calendar-year total returns, 2016–2025 2016: −36.5%; 2017: +55.6%; 2018: −17.5%; 2019: +62.6%; 2020: +30.8%; 2021: −22.4%; 2022: −35.4%; 2023: −1.6%; 2024: −0.9%; 2025: +63.8% −37% 2016 +56% 2017 −18% 2018 +63% 2019 +31% 2020 −22% 2021 −35% 2022 −2% 2023 −1% 2024 +64% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
BBC+63.8%−4.3%+3.3%
Technology Sector median+24.0%+10.0%+16.7%

Source: Fund prospectus, as of Dec 31, 2025

Full BBC performance history →

What BBC costs

On a $10,000 investment, BBC's 0.65% expense ratio costs about $65 a year. The prospectus estimates $810 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.

See the full BBC fee table →

BBC top 10 holdings

#Holding% of fund
1Dreyfus Government Cash Manage3.48%
2First Tracks Biotherapeutics Inc TRAX1.67%
3Mbx Biosciences Inc MBX1.24%
4Ataibeckley Inc ATAI1.23%
5Monopar Therapeutics Inc MNPR1.21%
6Definium Therapeutics Inc DFTX1.18%
7Xencor Inc XNCR1.10%
8Zenas Biopharma Inc ZBIO1.06%
9Uniqure Nv QURE1.06%
10Apogee Therapeutics Inc APGE1.02%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 14.3% of the fund. See all top 25 holdings and asset mix →

Alternatives to BBC

More funds like BBC →

BBC FAQ

What is the expense ratio of BBC?
BBC's expense ratio is 0.65%, which works out to about $65 a year for every $10,000 invested. The prospectus estimates total costs of $810 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is BBC a good investment?
It depends on your goals, but the data points to: 5-year return in the bottom quarter of its category; small fund ($46.4 million) — small funds are likelier to close. This is general information, not personalized advice.
What does BBC hold?
BBC's largest holdings are Dreyfus Government Cash Manage (3.5%), First Tracks Biotherapeutics Inc (1.7%), Mbx Biosciences Inc (1.2%), Ataibeckley Inc (1.2%), Monopar Therapeutics Inc (1.2%). It holds 132 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is BBC's 5-year return?
BBC returned −4.3% a year over the five years ending Dec 31, 2025, and +3.3% a year over ten years. Past performance does not guarantee future results.
Who manages BBC?
BBC is offered by Virtus through ETFis Series Trust I.